Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immunogenicity and safety study of a recombinant 9-valent HPV vaccine in healthy Chinese females aged 9-26 years
CTR20220679Phase 3Active
- Sponsor
- Beijing Health Guard
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus 9-valent vaccine, recombinant in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), anal intraepithelial neoplasia (AIN), sponsored by Beijing Health Guard. Started Mar 2022; status: active.
02
Drugs
human papillomavirus 9-valent vaccine, recombinant
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on CTR20220679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220679.